Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor that blocks B‐cell receptor signaling, is an effective therapy for patients with CLL although it does not completely eradicate disease.40 The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.